Pre-earnings options volume in BridgeBio (BBIO) Pharma is 1.3x normal with puts leading calls 10:7. Implied volatility suggests the market is anticipating a move near 8.2%, or $3.00, after results are released. Median move over the past eight quarters is 1.4%.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio announces UK MHRA marketing authorization for acoramidis
- BridgeBio Pharma: Anticipated Q1 Outperformance and Sustained Buy Rating Despite Rising R&D Expenses
- Buy Recommendation for BridgeBio Pharma Driven by Promising ATTR-CM Launch and Late-Stage Portfolio Potential
- BridgeBio price target raised to $53 from $49 at H.C. Wainwright
- BridgeBio management to meet with Piper Sandler